文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

无创正压通气与经鼻高流量氧疗对COVID-19合并ARDS患者临床疗效的影响

[Effect of noninvasive positive pressure ventilation and high-flow nasal cannula oxygen therapy on the clinical efficacy of coronavirus disease 2019 patients with acute respiratory distress syndrome].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2021-01-01
一句话结论回顾性研究显示,与HFNC相比,NIPPV未显著降低COVID-19合并ARDS患者的插管率和病死率,但可显著提高S/F比值。

该回顾性研究纳入2020年2月至4月武汉同济医院41例COVID-19合并ARDS(S/F比值<235)患者,按氧疗方式分为NIPPV组(24例)和HFNC组(17例)。NIPPV组并发症比例更高、淋巴细胞百分比更低,但血液净化需求更低。NIPPV组治疗2小时后S/F比值逐渐升高、呼吸频率逐渐下降,HFNC组S/F比值下降、呼吸频率升高,但两组各时间点S/F比值差异无统计学意义。两组插管率和住院病死率差异无统计学意义。氧疗方式和入院时病程是影响S/F比值的因素。

要点

  • 在COVID-19合并ARDS(S/F<235)患者中,与HFNC相比,NIPPV未显著降低插管率[66.7%(16/24)vs. 70.6%(12/17)]和住院病死率[58.3%(14/24)vs. 52.9%(9/17)]。
  • NIPPV组治疗2小时后呼吸频率显著高于HFNC组[30(27-33)次/min vs. 24(21-27)次/min,P<0.05]。
  • NIPPV组并发症比例高于HFNC组[87.5%(21/24)vs. 41.2%(7/17),P<0.05],淋巴细胞百分比低于HFNC组[5.3%(3.4%-7.8%)vs. 10.0%(3.9%-19.7%),P<0.05]。
  • NIPPV组需血液净化比例显著低于HFNC组[0%(0/24)vs. 29.4%(5/17),P<0.05]。
  • 氧疗方式和入院时病程是S/F比值的独立影响因素(β值分别为-15.827和1.202,P值分别为0.019和0.014)。

适用人群与场景

  • 2020年2月至4月华中科技大学同济医学院附属同济医院收治的COVID-19患者,以S/F比值<235代替氧合指数诊断ARDS,按氧疗方式分为NIPPV组和HFNC组。

诊断标准与关键阈值

  • 以脉搏血氧饱和度/吸入氧浓度(SpO2/FiO2,S/F)比值<235代替氧合指数(PaO2/FiO2)诊断ARDS。

处置流程与药物剂量

  • 原文未提及具体的NIPPV参数设置、HFNC流速/氧浓度设置、药物剂量或治疗疗程。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:回顾性研究;样本量:41例;中心数:单中心(华中科技大学同济医学院附属同济医院);人群:COVID-19合并ARDS(S/F<235)患者。
  • 干预与对照:NIPPV组(24例)vs. HFNC组(17例)。
  • 主要终点结果:插管率NIPPV组66.7%(16/24)vs. HFNC组70.6%(12/17),住院病死率NIPPV组58.3%(14/24)vs. HFNC组52.9%(9/17),差异均无统计学意义(均P>0.05)。
  • 关键次要终点:NIPPV组治疗2小时后呼吸频率显著高于HFNC组[30(27-33)次/min vs. 24(21-27)次/min,P<0.05];两组各时间点S/F比值差异无统计学意义。
  • 不良事件:NIPPV组并发症比例87.5%(21/24)vs. HFNC组41.2%(7/17),P<0.05;NIPPV组需血液净化比例0%(0/24)vs. HFNC组29.4%(5/17),P<0.05。

证据类型、等级与局限

  • 证据类型:回顾性研究;单中心、样本量小(41例)、非随机分组,原文未提及证据等级或推荐强度。

对床旁实践的改变

  • 在COVID-19合并ARDS(S/F<235)患者中,NIPPV与HFNC在插管率和住院病死率方面无显著差异,选择氧疗方式时需结合患者耐受性和并发症情况个体化决策。
  • NIPPV组并发症比例更高、淋巴细胞百分比更低,提示病情更重的患者可能更倾向于接受NIPPV,临床解读结果时需注意基线差异。
  • NIPPV组需血液净化比例更低,但原文未说明其原因,不能据此推断NIPPV具有肾脏保护作用。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To observe the effect of noninvasive positive pressure ventilation (NIPPV) and high-flow nasal cannula oxygen therapy (HFNC) on the prognosis of patients with coronavirus disease 2019 (COVID-19) accompanied with acute respiratory distress syndrome (ARDS).

METHODS: A retrospective study was conducted in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology when authors worked as medical team members for treating COVID-19. COVID-19 patients with pulse oxygen saturation/fraction of inspiration oxygen (SpO2/FiO2, S/F) ratio < 235, managed by medical teams [using S/F ratio instead of oxygenation index (PaO2/FiO2) to diagnose ARDS] from February to April 2020 were included. The patients were divided into NIPPV group and HFNC group according to their oxygen therapy modes. Clinical data of patients were collected, including general characteristics, respiratory rate (RR), fraction of FiO2, SpO2, heart rate (HR), mean arterial pressure (MAP), S/F ratio in the first 72 hours, lymphocyte count (LYM), percentage of lymphocyte (LYM%) and white blood cell count (WBC) at admission and discharge or death, the duration of dyspnea before NIPPV and HFNC, and the length from onset to admission. The differences of intubation rate, all-cause mortality, S/F ratio and RR were analyzed, and single factor analysis and generalized estimation equation (GEE) were used to analyze the risk factors affecting S/F ratio.

RESULTS: Among the 41 patients, the proportion of males was high (68.3%, 28 cases), the median age was 68 (58-74) years old, 28 cases had complications (68.3%), and 34 cases had multiple organ dysfunction syndrome (MODS, 82.9%). Compared with HFNC group, the proportion of complications in NIPPV group was higher [87.5% (21/24) vs. 41.2% (7/17), P < 0.05], and the value of LYM% was lower [5.3% (3.4%-7.8%) vs. 10.0% (3.9%-19.7%), P < 0.05], the need of blood purification was also significantly lower [0% (0/24) vs. 29.4% (5/17), P < 0.05]. The S/F ratio of NIPPV group gradually increased after 2 hours treatment and RR gradually decreased with over time, S/F ratio decreased and RR increased in HFNC group compared with baseline, but there was no significant difference in S/F ratio between the two groups at each time point. RR in NIPPV group was significantly higher than that in HFNC group after 2 hours treatment [time/min: 30 (27-33) vs. 24 (21-27), P < 0.05]. There was no significant difference in rate need intubation and hospital mortality between NIPPV group and HFNC group [66.7% (16/24) vs. 70.6% (12/17), 58.3% (14/24) vs. 52.9% (9/17), both P > 0.05]. Analysis of the factors affecting the S/Fratio in the course of oxygen therapy showed that the oxygen therapy mode and the course of illness at admission were the factors affecting the S/F ratio of patients [βvalues were -15.827, 1.202, 95% confidence interval (95%CI) were -29.102 to -2.552 and 0.247-2.156, P values were 0.019 and 0.014, respectively].

CONCLUSIONS: Compared with HFNC, NIPPV doesn't significantly reduce the intubation rate and mortality of patients with COVID-19 accompanied with ARDS, but it significantly increases the S/F ratio of those patients.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhao Z, Cao H, Cheng Q, et al. [Effect of noninvasive positive pressure ventilation and high-flow nasal cannula oxygen therapy on the clinical efficacy of coronavirus disease 2019 patients with acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34296691. doi:10.3760/cma.j.cn121430-20210104-00002

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。